Investigator-Initiated Studies (IISs)

BTG is committed to supporting independent research on TheraSphere in the form of IISs which broaden the understanding of TheraSphere™ and its application across a number of diseases with the ultimate goal of optimizing patient outcomes.

The support BTG provides for IISs offers a unique opportunity for physicians to explore areas of mutual scientific interest and thereby add to the body of scientific knowledge and evidence around disease management and the role TheraSphere can play.

TheraSphere continues to be studied in different oncological diseases, as part of a comprehensive oncological treatment plan, and in patient populations with unmet needs.

If you have specific questions about the IIS program at BTG, please email us at